The Müllerian duct (MD) forms the female reproductive tract (FRT) consisting of the oviducts, uterus, cervix, and upper vagina. FRT function is vital to fertility, providing the site of fertilization, embryo implantation and fetal development. Developmental defects in the formation and diseases of the FRT, including cancer and endometriosis, are prevalent in humans and can result in infertility and death. Furthermore, because the MDs are initially formed regardless of genotypic sex, mesenchymal to epithelial signaling is required in males to mediate MD regression and prevents the development of MD-derived organs. In males, defects in MD regression result in the retention of FRT organs and have been described in several human syndromes. Although to date not reported in humans, ectopic activation of MD regression signaling components in females can result in aplasia of the FRT. Clearly, MD development is important to human health; however, the molecular mechanisms remain largely undetermined. Molecular genetics studies of human diseases and mouse models have provided new insights into molecular signaling during MD development, regression and differentiation. This review will provide an overview of MD development and important genes and signaling mechanisms involved.

Allard S, Adin P, Gouedard L, di Clemente N, Josso N, et al: Molecular mechanisms of hormone-mediated Müllerian duct regression: involvement of beta-catenin. Development 127:3349-3360 (2000).
Arango NA, Lovell-Badge R, Behringer RR: Targeted mutagenesis of the endogenous mouse Mis gene promoter: in vivo definition of genetic pathways of vertebrate sexual development. Cell 99:409-419 (1999).
Arango NA, Szotek PP, Manganaro TF, Oliva E, Donahoe PK, Teixeira J: Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol 288:276-283 (2005).
Arango NA, Kobayashi A, Wang Y, Jamin SP, Lee HH, et al: A mesenchymal perspective of Müllerian duct differentiation and regression in Amhr2-lacZ mice. Mol Reprod Dev 75:1154-1162 (2008).
Austin HB: DiI analysis of cell migration during Müllerian duct regression. Dev Biol 169:29-36 (1995).
Barakat AY, Papadopoulou ZL, Chandra RS, Hollerman CE, Calcagno PL: Pseudohermaphroditism, nephron disorder and Wilms' tumor: a unifying concept. Pediatrics 54:366-369 (1974).
Barbacci E, Reber M, Ott MO, Breillat C, Huetz F, Cereghini S: Variant hepatocyte nuclear factor 1 is required for visceral endoderm specification. Development 126:4795-4805 (1999).
Behringer RR: The in vivo roles of Müllerian-inhibiting substance. Curr Top Dev Biol 29:171-187 (1994).
Behringer RR, Cate RL, Froelick GJ, Palmiter RD, Brinster RL: Abnormal sexual development in transgenic mice chronically expressing Müllerian inhibiting substance. Nature 345:167-170 (1990).
Behringer RR, Finegold MJ, Cate RL: Müllerian-inhibiting substance function during mammalian sexual development. Cell 79:415-425 (1994).
Belville C, Josso N, Picard JY: Persistence of Müllerian derivatives in males. Am J Med Genet 89:218-223 (1999).
Belville C, Marechal JD, Pennetier S, Carmillo P, Masgrau L, et al: Natural mutations of the anti-Müllerian hormone type II receptor found in persistent Müllerian duct syndrome affect ligand binding, signal transduction and cellular transport. Hum Mol Genet 18:3002-3013 (2009).
Benson GV, Lim H, Paria BC, Satokata I, Dey SK, Maas RL: Mechanisms of reduced fertility in Hoxa-10 mutant mice: uterine homeosis and loss of maternal Hoxa-10 expression. Development 122:2687-2696 (1996).
Biason-Lauber A, Konrad D, Navratil F, Schoenle EJ: A WNT4 mutation associated with Müllerian-duct regression and virilization in a 46,XX woman. N Engl J Med 351:792-798 (2004).
Biason-Lauber A, De Filippo G, Konrad D, Scarano G, Nazzaro A, Schoenle EJ: WNT4 deficiency - a clinical phenotype distinct from the classic Mayer-Rokitansky-Kuster-Hauser syndrome: a case report. Hum Reprod 22:224-229 (2007).
Bingham C, Ellard S, Cole TR, Jones KE, Allen LI, et al: Solitary functioning kidney and diverse genital tract malformations associated with hepatocyte nuclear factor-1β mutations. Kidney Int 61:1243-1251 (2002).
Block K, Kardana A, Igarashi P, Taylor HS: In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing müllerian system. FASEB J 14:1101-1108. (2000).
Bouchard M, Souabni A, Mandler M, Neubuser A, Busslinger M: Nephric lineage specification by Pax2 and Pax8. Genes Dev 16:2958-2970 (2002).
Brembeck FH, Rosario M, Birchmeier W: Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 16:51-59 (2006).
Carroll TJ, Park JS, Hayashi S, Majumdar A, McMahon AP: Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions underlying organogenesis of the mammalian urogenital system. Dev Cell 9:283-292 (2005).
Cermik D, Selam B, Taylor HS: Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. J Clin Endocrinol Metab 88:238-243 (2003).
Cheng Z, Zhu Y, Su D, Wang J, Cheng L, et al: A novel mutation of HOXA10 in a Chinese woman with a Mullerian duct anomaly. Hum Reprod 26:3197-3201 (2011).
Coffinier C, Barra J, Babinet C, Yaniv M: Expression of the vHNF1/HNF1beta homeoprotein gene during mouse organogenesis. Mech Dev 89:211-213 (1999a).
Coffinier C, Thepot D, Babinet C, Yaniv M, Barra J: Essential role for the homeoprotein vHNF1/HNF1beta in visceral endoderm differentiation. Development 126:4785-4794 (1999b).
Coppes MJ, Liefers GJ, Higuchi M, Zinn AB, Balfe JW, Williams BR: Inherited WT1 mutation in Denys-Drash syndrome. Cancer Res 52:6125-6128 (1992).
Cox S, Smith L, Bogani D, Cheeseman M, Siggers P, Greenfield A: Sexually dimorphic expression of secreted frizzled-related (SFRP) genes in the developing mouse Müllerian duct. Mol Reprod Dev 73:1008-1016 (2006).
Davis RJ, Harding M, Moayedi Y, Mardon G: Mouse Dach1 and Dach2 are redundantly required for Müllerian duct development. Genesis 46:205-213 (2008).
Denys P, Malvaux P, Van Den Berghe H, Tanghe W, Proesmans W: Association of an anatomo-pathological syndrome of male pseudohermaphroditism, Wilms' tumor, parenchymatous nephropathy and XX/XY mosaicism (in French). Arch Fr Pediatr 24:729-739 (1967).
De Santa Barbara P, Bonneaud N, Boizet B, Desclozeaux M, Moniot B, et al: Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Müllerian hormone gene. Mol Cell Biol 18:6653-6665 (1998).
Deutscher E, Hung-Chang Yao H: Essential roles of mesenchyme-derived beta-catenin in mouse Müllerian duct morphogenesis. Dev Biol 307:227-236 (2007).
di Clemente N, Belville C: Anti-Müllerian hormone receptor defect. Best Pract Res Clin Endocrinol Metab 20:599-610 (2006).
Dohr G, Tarmann T, Schiechl H: Different antigen expression on Wolffian and Müllerian cells in rat embryos as detected by monoclonal antibodies. Anat Embryol (Berl) 176:239-242 (1987).
Dreyer C, Ellinger-Ziegelbauer H: Retinoic acid receptors and nuclear orphan receptors in the development of Xenopus laevis. Int J Dev Biol 40:255-262 (1996).
Dyche WJ: A comparative study of the differentiation and involution of the Müllerian duct and Wolffian duct in the male and female fetal mouse. J Morphol 162:175-209 (1979).
Ekici AB, Strissel PL, Oppelt PG, Renner SP, Brucker S, et al: HOXA10 and HOXA13 sequence variations in human female genital malformations including congenital absence of the uterus and vagina. Gene 518:267-272 (2013).
Farikullah J, Ehtisham S, Nappo S, Patel L, Hennayake S: Persistent Müllerian duct syndrome: lessons learned from managing a series of eight patients over a 10-year period and review of literature regarding malignant risk from the Müllerian remnants. BJU Int 110:E1084-E1089 (2012).
Filali M, Cheng N, Abbott D, Leontiev V, Engelhardt JF: Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter. J Biol Chem 277:33398-33410 (2002).
Folch M, Pigem I, Konje JC: Müllerian agenesis: etiology, diagnosis, and management. Obstet Gynecol Surv 55:644-649 (2000).
Franco HL, Dai D, Lee KY, Rubel CA, Roop D, et al: WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during embryo implantation and decidualization in the mouse. FASEB J 25:1176-1187 (2011).
Fujino A, Arango NA, Zhan Y, Manganaro TF, Li X, et al: Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct. Dev Biol 325:351-362 (2009).
Gao F, Maiti S, Sun G, Ordonez NG, Udtha M, et al: The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome. Mol Cell Biol 24:9899-9910 (2004).
Gendron RL, Paradis H, Hsieh-Li HM, Lee DW, Potter SS, Markoff E: Abnormal uterine stromal and glandular function associated with maternal reproductive defects in Hoxa-11 null mice. Biol Reprod 56:1097-1105 (1997).
Gervasini C, Grati FR, Lalatta F, Tabano S, Gentilin B, et al: SHOX duplications found in some cases with type I Mayer-Rokitansky-Kuster-Hauser syndrome. Genet Med 12:634-640 (2010).
Goodman FR, Scambler PJ: Human HOX gene mutations. Clin Genet 59:1-11 (2001).
Goodman FR, Bacchelli C, Brady AF, Brueton LA, Fryns JP, et al: Novel HOXA13 mutations and the phenotypic spectrum of hand-foot-genital syndrome. Am J Hum Genet 67:197-202 (2000).
Gruenwald P: The relation of the growing Müllerian duct to the Wolffian duct and its importance for the genesis of malformations. Anat Rec 81:1-19 (1941).
Guioli S, Sekido R, Lovell-Badge R: The origin of the Müllerian duct in chick and mouse. Dev Biol 302:389-398 (2007).
Hossain A, Saunders GF: Role of Wilms tumor 1 (WT1) in the transcriptional regulation of the Müllerian-inhibiting substance promoter. Biol Reprod 69:1808-1814 (2003).
Hurst CH, Abbott B, Schmid JE, Birnbaum LS: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) disrupts early morphogenetic events that form the lower reproductive tract in female rat fetuses. Toxicol Sci 65:87-98 (2002).
Hutson JM, Fallat ME, Kamagata S, Donahoe PK, Budzik GP: Phosphorylation events during Müllerian duct regression. Science 223:586-589 (1984).
Iizuka-Kogo A, Ishidao T, Akiyama T, Senda T: Abnormal development of urogenital organs in Dlgh1-deficient mice. Development 134:1799-1807 (2007).
Imhoff FM, Yang D, Mathew SF, Clarkson AN, Kawagishi Y, et al: The type 2 anti-Müllerian hormone receptor has splice variants that are dominant-negative inhibitors. FEBS Lett 587:1749-1753 (2013).
Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S: Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 272:22389-22392 (1997).
Jacob M, Konrad K, Jacob HJ: Early development of the Müllerian duct in avian embryos with reference to the human. An ultrastructural and immunohistochemical study. Cells Tissues Organs 164:63-81 (1999).
Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR: Requirement of Bmpr1a for Müllerian duct regression during male sexual development. Nat Genet 32:408-410 (2002).
Jeong JW, Lee HS, Franco HL, Broaddus RR, Taketo MM, et al: Beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus. Oncogene 28:31-40 (2009).
Josso N, Picard JY, Trah D: The antimullerian hormone. Recent Prog Horm Res 33:117-167 (1976).
Josso N, Cate RL, Picard JY, Vigier B, di Clemente N, et al: Anti-müllerian hormone: the Jost factor. Recent Prog Horm Res 48:1-59 (1993).
Kastner P, Mark M, Ghyselinck N, Krezel W, Dupe V, et al: Genetic evidence that the retinoid signal is transduced by heterodimeric RXR/RAR functional units during mouse development. Development 124:313-326 (1997).
Kawakami Y, Wada N, Nishimatsu S, Nohno T: Involvement of frizzled-10 in Wnt-7a signaling during chick limb development. Dev Growth Differ 42:561-569 (2000).
Klattig J, Sierig R, Kruspe D, Besenbeck B, Englert C: Wilms' tumor protein Wt1 is an activator of the anti-Müllerian hormone receptor gene Amhr2. Mol Cell Biol 27:4355-4364 (2007).
Kobayashi A, Behringer RR: Developmental genetics of the female reproductive tract in mammals. Nat Rev Genet 4:969-980 (2003).
Kobayashi A, Shawlot W, Kania A, Behringer RR: Requirement of Lim1 for female reproductive tract development. Development 131:539-549 (2004).
Kobayashi A, Stewart CA, Wang Y, Fujioka K, Thomas NC, et al: β-Catenin is essential for Müllerian duct regression during male sexual differentiation. Development 138:1967-1975 (2011).
Kolatsi-Joannou M, Bingham C, Ellard S, Bulman MP, Allen LI, et al: Hepatocyte nuclear factor-1β: a new kindred with renal cysts and diabetes and gene expression in normal human development. J Am Soc Nephrol 12:2175-2180 (2001).
Lapointe E, Boyer A, Rico C, Paquet M, Franco HL, et al: FZD1 regulates cumulus expansion genes and is required for normal female fertility in mice. Biol Reprod 87:104 (2012).
Ledig S, Schippert C, Strick R, Beckmann MW, Oppelt PG, Wieacker P: Recurrent aberrations identified by array-CGH in patients with Mayer-Rokitansky-Kuster-Hauser syndrome. Fertil Steril 95:1589-1594 (2011).
Ledig S, Brucker S, Barresi G, Schomburg J, Rall K, Wieacker P: Frame shift mutation of LHX1 is associated with Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome. Hum Reprod 27:2872-2875 (2012).
Lindner TH, Njolstad PR, Horikawa Y, Bostad L, Bell GI, Sovik O: A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1β. Hum Mol Genet 8:2001-2008 (1999).
Little M, Georgas K, Pennisi D, Wilkinson L: Kidney development: two tales of tubulogenesis. Curr Top Dev Biol 90:193-229 (2010).
Magro G, Grasso S: Expression of cytokeratins, vimentin and basement membrane components in human fetal male Müllerian duct and perimüllerian mesenchyme. Acta Histochem 97:13-18 (1995).
Manivel JC, Sibley RK, Dehner LP: Complete and incomplete Drash syndrome: a clinicopathologic study of five cases of a dysontogenetic-neoplastic complex. Hum Pathol 18:80-89 (1987).
Masse J, Watrin T, Laurent A, Deschamps S, Guerrier D, Pellerin I: The developing female genital tract: from genetics to epigenetics. Int J Dev Biol 53:411-424 (2009).
Mauch TJ, Yang G, Wright M, Smith D, Schoenwolf GC: Signals from trunk paraxial mesoderm induce pronephros formation in chick intermediate mesoderm. Dev Biol 220:62-75 (2000).
Mendelsohn C, Lohnes D, Decimo D, Lufkin T, LeMeur M, et al: Function of the retinoic acid receptors (RARs) during development (II). Multiple abnormalities at various stages of organogenesis in RAR double mutants. Development 120:2749-2771 (1994).
Mericskay M, Kitajewski J, Sassoon D: Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development 131:2061-2072 (2004).
Miller C, Sassoon DA: Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125:3201-3211 (1998).
Miller C, Pavlova A, Sassoon DA: Differential expression patterns of Wnt genes in the murine female reproductive tract during development and the estrous cycle. Mech Dev 76:91-99 (1998).
Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, et al: Genetic analysis of the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev 10:2577-2587 (1996).
Mishina Y, Whitworth DJ, Racine C, Behringer RR: High specificity of Müllerian-inhibiting substance signaling in vivo. Endocrinology 140:2084-2088 (1999).
Miyamoto N, Yoshida M, Kuratani S, Matsuo I, Aizawa S: Defects of urogenital development in mice lacking Emx2. Development 124:1653-1664 (1997).
Mortlock DP, Innis JW: Mutation of HOXA13 in hand-foot-genital syndrome. Nat Genet 15:179-180 (1997).
Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN, Hammer GD, Ingraham HA: Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 93:445-454 (1998).
Nunnally AP, Parr BA: Analysis of Fz10 expression in mouse embryos. Dev Genes Evol 214:144-148 (2004).
Obara-Ishihara T, Kuhlman J, Niswander L, Herzlinger D: The surface ectoderm is essential for nephric duct formation in intermediate mesoderm. Development 126:1103-1108 (1999).
Oppelt P, Strissel PL, Kellermann A, Seeber S, Humeny A, et al: DNA sequence variations of the entire anti-Müllerian hormone (AMH) gene promoter and AMH protein expression in patients with the Mayer-Rokitanski-Kuster-Hauser syndrome. Hum Reprod 20:149-157 (2005).
Oppelt P, Renner SP, Kellermann A, Brucker S, Hauser GA, et al: Clinical aspects of Mayer-Rokitansky-Kuester-Hauser syndrome: recommendations for clinical diagnosis and staging. Hum Reprod 21:792-797 (2006).
Orvis GD, Behringer RR: Cellular mechanisms of Müllerian duct formation in the mouse. Dev Biol 306:493-504 (2007).
Orvis GD, Jamin SP, Kwan KM, Mishina Y, Kaartinen VM, et al: Functional redundancy of TGF-beta family type I receptors and receptor-Smads in mediating anti-Müllerian hormone-induced Müllerian duct regression in the mouse. Biol Reprod 78:994-1001 (2008).
Paranko J, Virtanen I: Epithelial and mesenchymal cell differentiation in the fetal rat genital ducts: changes in the expression of cytokeratin and vimentin type of intermediate filaments and desmosomal plaque proteins. Dev Biol 117:135-145 (1986).
Parr BA, McMahon AP: Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a. Nature 395:707-710 (1998).
Picon R: Action of the fetal testis on the development in vitro of the Müllerian ducts in the rat [in French]. Arch Anat Microsc Morphol Exp 58:1-19 (1969).
Post LC, Margulies EH, Kuo A, Innis JW: Severe limb defects in hypodactyly mice result from the expression of a novel, mutant HOXA13 protein. Dev Biol 217:290-300 (2000).
Reber M, Cereghini S: Variant hepatocyte nuclear factor 1 expression in the mouse genital tract. Mech Dev 100:75-78 (2001).
Robert B, Lallemand Y: Anteroposterior patterning in the limb and digit specification: contribution of mouse genetics. Dev Dyn 235:2337-2352 (2006).
Roberts LM, Visser JA, Ingraham HA: Involvement of a matrix metalloproteinase in MIS-induced cell death during urogenital development. Development 129:1487-1496 (2002).
Salehi P, Koh CJ, Pitukcheewanont P, Trinh L, Daniels M, Geffner M: Persistent Müllerian duct syndrome: 8 new cases in Southern California and a review of the literature. Pediatr Endocrinol Rev 10:227-233 (2012).
Sandbacka M, Laivuori H, Freitas E, Halttunen M, Jokimaa V, et al: TBX6, LHX1 and copy number variations in the complex genetics of Müllerian aplasia. Orphanet J Rare Dis 8:125 (2013).
Saxen L, Sariola H: Early organogenesis of the kidney. Pediatr Nephrol 1:385-392 (1987).
Shen WH, Moore CC, Ikeda Y, Parker KL, Ingraham HA: Nuclear receptor steroidogenic factor 1 regulates the Müllerian inhibiting substance gene: a link to the sex determination cascade. Cell 77:651-661 (1994).
Tanwar PS, Zhang L, Tanaka Y, Taketo MM, Donahoe PK, Teixeira JM: Focal Müllerian duct retention in male mice with constitutively activated β-catenin expression in the Müllerian duct mesenchyme. Proc Natl Acad Sci USA 107:16142-16147 (2010).
Taylor HS, Vanden Heuvel GB, Igarashi P: A conserved Hox axis in the mouse and human female reproductive system: late establishment and persistent adult expression of the Hoxa cluster genes. Biol Reprod 57:1338-1345 (1997).
Taylor HS, Igarashi P, Olive DL, Arici A: Sex steroids mediate HOXA11 expression in the human peri-implantation endometrium. J Clin Endocrinol Metab 84:1129-1135 (1999).
Torres M, Gomez-Pardo E, Dressler GR, Gruss P: Pax-2 controls multiple steps of urogenital development. Development 121:4057-4065 (1995).
Trelstad RL, Hayashi A, Hayashi K, Donahoe PK: The epithelial-mesenchymal interface of the male rate Müllerian duct: loss of basement membrane integrity and ductal regression. Dev Biol 92:27-40 (1982).
Troy PJ, Daftary GS, Bagot CN, Taylor HS: Transcriptional repression of peri-implantation EMX2 expression in mammalian reproduction by HOXA10. Mol Cell Biol 23:1-13 (2003).
Tsuji M, Shima H, Yonemura CY, Brody J, Donahoe PK, Cunha GR: Effect of human recombinant Müllerian inhibiting substance on isolated epithelial and mesenchymal cells during Müllerian duct regression in the rat. Endocrinology 131:1481-1488 (1992).
Urioste M, Rodriguez JI, Barcia JM, Martin M, Escriba R, et al: Persistence of Müllerian derivatives, lymphangiectasis, hepatic failure, postaxial polydactyly, renal and craniofacial anomalies. Am J Med Genet 47:494-503 (1993).
Vadlamudi U, Espinoza HM, Ganga M, Martin DM, Liu X, et al: PITX2, beta-catenin and LEF-1 interact to synergistically regulate the LEF-1 promoter. J Cell Sci 118:1129-1137 (2005).
Vainio S, Heikkila M, Kispert A, Chin N, McMahon AP: Female development in mammals is regulated by Wnt-4 signalling. Nature 397:405-409 (1999).
van Genderen C, Okamura RM, Farinas I, Quo RG, Parslow TG, et al: Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev 8:2691-2703 (1994).
Viebahn C, Lane EB, Ramaekers FC: The mesonephric (Wolffian) and paramesonephric (Müllerian) ducts of golden hamsters express different intermediate-filament proteins during development. Differentiation 34:175-188 (1987).
Warot X, Fromental-Ramain C, Fraulob V, Chambon P, Dolle P: Gene dosage-dependent effects of the Hoxa-13 and Hoxd-13 mutations on morphogenesis of the terminal parts of the digestive and urogenital tracts. Development 124:4781-4791 (1997).
Warr N, Siggers P, Bogani D, Brixey R, Pastorelli L, et al: Sfrp1 and Sfrp2 are required for normal male sexual development in mice. Dev Biol 326:273-284 (2009).
Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, et al: Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression. Development 133:2359-2369 (2006).
Zhao Y, Potter SS: Functional specificity of the Hoxa13 homeobox. Development 128:3197-3207 (2001).
Zhu C, Zhao F, Zhang W, Wu H, Chen Y, et al: A familial WT1 mutation associated with incomplete Denys-Drash syndrome. Eur J Pediatr 172:1357-1362 (2013).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.